Evidence map›Paper›PMID 42598089›Full record

ArticleSynthetic and systems biotechnology2027

Production improvement of dalbavancin precursor A40926B0 in

Xue-Yan Liu, Yan-Qiu Liu, Yi-Lei Zheng, Jing-Yi Ruan, Peng Fang, Jiao-Le Fang, Xin-Ai Chen, Qing-Wei Zhao, Zhong-Yuan Lyu, Yong-Quan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic and systems biotechnology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xue-Yan LiuFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Yan-Qiu LiuFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Yi-Lei ZhengFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Jing-Yi RuanZhejiang Provincial Key Laboratory of Synthetic Biotechnology for Microbial Medicine, Taizhou, Zhejiang Province, China.
Peng FangZhejiang Provincial Key Laboratory of Synthetic Biotechnology for Microbial Medicine, Taizhou, Zhejiang Province, China.
Jiao-Le FangFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Xin-Ai ChenFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Qing-Wei ZhaoFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Zhong-Yuan LyuInstitute of Biopharmaceuticals, School of Pharmaceutical Sciences, Taizhou University, Taizhou, Zhejiang Province, China.
Yong-Quan LiFirst Affiliated Hospital and Institute of Pharmaceutical Biotechnology, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dalbavancin is a potent next-generation lipoglycopeptide antibiotic, but the biosynthesis of its essential precursor, A40926B0, is severely hindered in its native producer Nonomuraea gerenzanensis. Complex competing metabolic pathways and strict transcriptional repression in this strain lead to critical industrial bottlenecks, including extreme product heterogeneity and notoriously low yields. To address these challenges, this study presents a systematic strategy to construct a high-producing strain and optimize the fermentation process for A40926B0. First, random mutagenesis of the strain

Indexed as

A40926B0DalbavancinEndogenous promoter screeningFermentation optimization

Identifiers

PMID42598089
PMCPMC13470283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.